Why Public Health Agencies Cannot Depend on Good Laboratory Practices as a Criterion for Selecting Data: The Case of Bisphenol A
No Thumbnail Available
Authors
Myers, John Peterson
vom Saal, Frederick S.
Akingbemi, Benson T.
Arizono, Koji
Belcher, Scott
Colborn, Theo
Chahoud, Ibrahim
Crain, D. Andrew, 1970-
Farabollini, Francesca
Guillette, Louis J., 1954-
Hassold, Terry J.
Ho, Shuk-mei
Hunt, Patricia A.
Iguchi, Taisen, 1951-
Jobling, Susan
Kanno, Jun
Laufer, Hans, 1929-
Marcus, Michele
McLachlan, John A.
Nadal, Angel
Oehlmann, Jörg
Olea, Nicolás
Palanza, Paola
Parmigiani, Stefano
Rubin, Beverly S.
Schoenfelder, Gilbert
Sonnenschein, C. (Carlos)
Soto, A. M. (Ana M.)
Talsness, Chris E.
Taylor, Julia A.
Vandenberg, Laura N.
Vandenbergh, John G.
Vogel, Sarah
Watson, Cheryl S., 1950-
Welshons, Wade V.
Zoeller, R. Thomas
vom Saal, Frederick S.
Akingbemi, Benson T.
Arizono, Koji
Belcher, Scott
Colborn, Theo
Chahoud, Ibrahim
Crain, D. Andrew, 1970-
Farabollini, Francesca
Guillette, Louis J., 1954-
Hassold, Terry J.
Ho, Shuk-mei
Hunt, Patricia A.
Iguchi, Taisen, 1951-
Jobling, Susan
Kanno, Jun
Laufer, Hans, 1929-
Marcus, Michele
McLachlan, John A.
Nadal, Angel
Oehlmann, Jörg
Olea, Nicolás
Palanza, Paola
Parmigiani, Stefano
Rubin, Beverly S.
Schoenfelder, Gilbert
Sonnenschein, C. (Carlos)
Soto, A. M. (Ana M.)
Talsness, Chris E.
Taylor, Julia A.
Vandenberg, Laura N.
Vandenbergh, John G.
Vogel, Sarah
Watson, Cheryl S., 1950-
Welshons, Wade V.
Zoeller, R. Thomas
Meeting name
Sponsors
Date
Journal Title
Format
Article
Abstract
We reviewed differences between industry-funded GLP studies of BPA conducted by commercial laboratories for regulatory purposes and non-GLP studies conducted in academic and government laboratories to identify hazards and molecular mechanisms mediating adverse effects. We examined the methods and results in the GLP studies that were pivotal in the draft decision of the U.S. FDA declaring BPA safe in relation to findings from studies that were competitive for U.S. National Institutes of Health (NIH) funding, peer-reviewed for publication in leading journals, subject to independent replication, but rejected by the U.S. FDA for regulatory purposes.